Holmes Biopharma, Inc.: Launches International Media Campaign

SCOTTSDALE, ARIZONA announces the launch of an extensive six month, high performance media campaign.

Through the services of TVA Productions in California, Holmes Biopharma has created a 15 minute video profile and a 1 minute media profile that will be featured on top networks such as Fox News Channel, CNN, MSNBC, CNBC, the Discovery and Biography Channels, the German news station NTV and many local stations. Holmes Biopharma's media campaign will be viewed by more than 300 million people worldwide.

The scope of the Holmes Biopharma's promotional campaign will be international and the video broadcasts will be shown in 45 million homes in Western Europe as well as featured in-flight programming on targeted airlines. The episode will be broadcasted on the internet from a suite of financial web sites and through WorldNetCast.com where it is guaranteed to reach 10 million visitors.

The Company's profile will be featured in newspaper articles that will run in highly circulated papers with a readership of 20 million. Radio news releases will be distributed to 6,600 radio stations on the regular news and talk shows.

"Our extensive media campaign will introduce our dynamic and growing company to the entire world. We are excited to raise the company's level of awareness and market exposure to new investors and customers globally," stated John Metcalfe, President CEO, Holmes Biopharma, Inc.

About Holmes:

Holmes Biopharma, Inc. and its wholly owned subsidiary, Qualia Clinical Service, Inc. is a contract research organization focused on providing integrated and cost effective clinical development services. Currently, clinics operate in Omaha, Nebraska USA, Toronto, Canada. and Kiev, Ukraine, Eastern Europe. For more information about the company please visit our website at www.holmesbiopharma.com.

On behalf of the Board of Directors

John F. Metcalfe, President

Certain statements in this press release constitute "forward looking statements" within the meaning of the United States Securities Legislation. The Company's actual results could differ from those in the forward-looking statements. Do not construe this information as investment advice. This is not a solicitation to buy or sell securities. This does not purport to be a complete analysis of the Company. Investing in securities is speculative and carries a high degree of risk. Past performance does not guarantee future results. Readers should consult their own independent advisers with any investment, including any contemplated investment. All information contained in this press release should be independently investigated. This press release contains forward-looking statements. These remarks involve risks and uncertainties. Risks are not limited to quarterly fluctuations in results or the companies' management of growth and competition. Other risks are detailed in the Company's SEC filings. Actual results may differ materially from such information set forth herein.

Contacts: Holmes Biopharma, Inc. John F. Metcalfe President 1-800-778-4990 Email: ir@holmesbiopharma.com Website: www.holmesbiopharma.com

Swiftsure (CE) (USOTC:HLMB)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024